Published Date:2020-10-28 Original Link:https://www.onenessbio.com/en/news_detail68_1.htm No 1 Date of announcement 2020/10/28 Time of announcement  01:22:39 Subject Oneness Biotech Co., LTD. receives a Mexican patent titled “TOPICAL FORMULATION FOR PROMOTING WOUND HEALING” on Fespixon cream (Research code: ON101).      To which item it meets paragraph 53 Date of events 2020/10/28 Statement  1.Date of occurrence of the...Read More

Published Date:2020-05-26 Original Link:https://www.onenessbio.com/en/news_detail108_1.htm Contact Us繁簡ENRead More

Published Date:2020-05-14 Original Link:https://www.onenessbio.com/en/news_detail109_1.htm Contact Us繁簡ENRead More

Published Date:2020-02-25 Original Link:https://www.onenessbio.com/en/news_detail80_1.htm Contact Us繁簡ENRead More

Published Date:2020-02-11 Original Link:https://www.onenessbio.com/en/news_detail78_1.htm Contact Us繁簡ENRead More

Published Date:2020-01-03 Original Link:https://www.onenessbio.com/en/news_detail76_1.htm Contact Us繁簡ENRead More

Published Date:2019-12-16 Original Link:https://www.onenessbio.com/en/news_detail101_1.htm Contact Us繁簡ENRead More

Published Date:2019-12-13 Original Link:https://www.onenessbio.com/en/news_detail102_1.htm Contact Us繁簡ENRead More

  BfArM, the German Federal Institute for Drugs and Medical Devices has confirmed acceptance of the IND application of Oneness Biotech for Phase 3 trial of diabetic foot ulcer new drug, ON101 (protocol#ON101CLCT04).Read More

  The merger between Oneness Biotech and Fountain Biopharma makes the pipeline and resources integrated. The pipeline will include a late-stage drug to be launched in global market as well as new drugs in earlier clinical stage in immunology. This merger will strengthen the R&D capability in favor of global collaboration and competition.Read More